Categories: NewsPharmaceutical

Optimi Health Announces Leadership Transition

Vancouver, British Columbia–(Newsfile Corp. – October 21, 2024) – Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) (“Optimi” or the “Company“), a GMP-compliant, Health Canada-licensed manufacturer of psychedelics specializing in botanical psilocybin and MDMA, today announced that Mr. William (Bill) Ciprick will be stepping down as Chief Executive Officer due to personal reasons.

“During his three years of leadership, Bill has played a key role in bringing Optimi’s GMP psychedelics to market and to patients in Australia,” said Optimi Co-Founder and Chair of the Board, JJ Wilson. “The Board of Directors extends its deepest gratitude for his dedication and leadership, which have been instrumental in establishing the Company’s industry presence. We are pleased that Bill will continue to support the Company in an advisory capacity throughout this transition.”

Effective immediately, the Board has appointed Mr. Dane Stevens, Co-Founder of Optimi, as Interim Chief Executive Officer. In this role, Mr. Stevens will continue to advance the Company’s key initiatives, with a focus on business development, expanding revenue opportunities, and maintaining the Company’s strategic direction.

About Optimi Health Corp.

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) is a leading psychedelics pharmaceutical manufacturer licensed by Health Canada. Specializing in controlled substances such as botanical psilocybin and MDMA, Optimi is dedicated to supplying safe, GMP-grade products and APIs to researchers, drug developers, and authorized patients worldwide. Optimi’s facilities in Princeton, British Columbia, are designed for the development of proprietary formulations under strict GACP and GMP standards, ensuring unparalleled quality and reliability. The Company is committed to being the most trusted supplier of safe psychedelic drug candidates globally.

On behalf of the Board of Directors,
OPTIMI HEALTH CORP.

JJ Wilson, Chair of the Board

For more information, please contact the Company at:
Telephone: (778) 761-4551
investors@optimihealth.ca
www.optimihealth.ca

Forward-Looking Statements

This news release contains forward-looking statements and forward-looking information within the meaning of Canadian securities legislation (collectively, “forward-looking statements”) that relate to Optimi’s current expectations and views of future events. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions, or future events or performance (often, but not always, through the use of words or phrases such as “will likely result,” “are expected to,” “expects,” “will continue,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical facts and may be forward-looking statements. These statements may involve estimates, assumptions, and uncertainties that could cause actual results or outcomes to differ materially from those expressed in such forward-looking statements. No assurance can be given that these expectations will prove to be correct, and such forward-looking statements included in this news release should not be unduly relied upon. These statements speak only as of the date of this news release.

Forward-Looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond Optimi’s control, which could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Optimi undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. New factors emerge from time to time, and it is not possible for Optimi to predict all of them or assess the impact of each factor or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Any forward-looking statements contained in this news release are expressly qualified in their entirety by this cautionary statement.

Neither the Canadian Securities Exchange nor the Canadian Investment Regulatory Organization accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/227241

Staff

Recent Posts

Sona Nanotech Issued Patent and Appoints New Board Member

Halifax, Nova Scotia--(Newsfile Corp. - October 21, 2024) - Sona Nanotech Inc. (CSE: SONA) (OTCQB:…

9 mins ago

Legacy ER & Urgent Care Prosper Now Open

The Largest Dual Facility in Texas Expands Intuitive Health's Innovative Health Care Model to Prosper…

2 hours ago

Axxess Names Tim Ingram Executive Vice President for Talent Acquisition To Ensure New Hires Reinforce Its Award-Winning Culture As Company Grows Worldwide

DALLAS, Oct. 21, 2024 /PRNewswire/ -- Longtime Axxess leader Tim Ingram has been named Executive Vice…

5 hours ago

Osteotec appointed as Novastep’s exclusive distribution agent for the UK, Ireland and Nordic markets

NEWBURY, England, Oct. 21, 2024 /PRNewswire/ -- Osteotec, the market leading manufacturer and distributor of…

5 hours ago

Spatially Health Partners with Janus Healthcare Partners to Expand Access to Behavioral Health Services and Tackle Social Determinants of Health (SDOH) for its Patients

Spatially Health's Equity Equalizer™ advanced technology will provide critical insights to support Janus Health Partners'…

5 hours ago

Bioprocessing Market Size Worth $72.55 Billion, Globally, by 2031 – Exclusive Report by The Insight Partners

The Bioprocessing Market share is expected to reach US$ 72.55 billion by 2031 from US$ 25.35…

5 hours ago